Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712498 | 0.87 | NFE2L2 (0.39) | NFE2L2HTR2CPTGS1PTGS2HTR2A | |
| SCHEMBL23091825 | 0.87 | NFE2L2 (0.39) | NFE2L2HTR2CPTGS1PTGS2HTR2A | |
| SCHEMBL21723206 | 0.87 | NFE2L2 (0.39) | NFE2L2HTR2CPTGS1PTGS2HTR2A | |
| SCHEMBL27399257 | 0.78 | CHRNB2 (0.43) | CHRNB2CHRNA4HTR2CHTR2AHTR2B | |
| SCHEMBL862515 | 0.76 | NFE2L2 (0.68) | NFE2L2HTR2CPTGS1PTGS2HTR2A | |
| SCHEMBL22462808 | 0.74 | NFE2L2 (0.39) | NFE2L2 | |
| SCHEMBL23091781 | 0.74 | NFE2L2 (0.39) | NFE2L2 | |
| SCHEMBL10019543 | 0.74 | NFE2L2 (0.39) | NFE2L2MAOAMAOB | |
| SCHEMBL13535962 | 0.71 | NFE2L2 (0.56) | NFE2L2PTGS1PTGS2 | |
| SCHEMBL25686111 | 0.71 | NFE2L2 (0.56) | NFE2L2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-06-30 | — | — | US | disclosed |
| CN-112867720-A | Novel heterocyclic compounds as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021048241-A1 | RADIOLABELED COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-18 | — | — | WO | disclosed |
| CN-112469724-A | Novel heterocyclic compounds as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | NFE2L2 4698/4885CHRNB2 2104/4885CHRNA4 2530/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | NFE2L2 4082/4885CHRNB2 3838/4885CHRNA4 4155/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | NFE2L2 4082/4885CHRNB2 3838/4885CHRNA4 4155/4885 |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, MGLL, LPL | NFE2L2 4075/4885CHRNB2 3749/4885CHRNA4 4136/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | NFE2L2 4082/4885CHRNB2 3838/4885CHRNA4 4155/4885 |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | MGLL, PNLIP, LPL | NFE2L2 4233/4885CHRNB2 4206/4885CHRNA4 4410/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | NFE2L2 4082/4885CHRNB2 3838/4885CHRNA4 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.